NEWS & RESOURCES AllPublicationsAltesa Biosciences Secures $75 Million Series B Following Positive Phase 2a Rhinovirus Challenge Study in COPD Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Mucosal type 2 innate lymphoid cells are a key component of the allergic response to aeroallergens. Oxidative and nitrosative stress and histone deacetylase-2 activity in exacerbations of COPD. Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences’ Lead Medicine into Advanced Clinical Trials Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Role of deficient type III interferon-lambda production in asthma exacerbations. St Mary’s Hospital Questionnaire Vapendavir for rhinovirus-triggered COPD exacerbations: phase 2a study results VirTus Supports Development of Apollo Therapeutics’ APL-10456 St Mary’s Hospital Clinical Trial Questionnaire
